Australia markets open in 4 hours 55 minutes

Trinity Biotech plc (TRIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4000+0.0200 (+1.45%)
As of 02:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.3800
Open1.3500
Bid1.3600 x 800
Ask1.4100 x 800
Day's range1.3500 - 1.4200
52-week range0.8600 - 3.0500
Volume19,355
Avg. volume59,562
Market cap53.351M
Beta (5Y monthly)1.33
PE ratio (TTM)35.00
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date05 June 2015
1y target estN/A
  • GlobeNewswire

    Trinity Biotech Announces Quarter 1 2022 Financial Results

    DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022. Quarter 1 Results Total revenues for Q1, 2022 were $18.8m compared to $25.6m in Q1, 2021, a decrease of 26.6% as indicated below: 2021Quarter 12022Quarter 1Increase/(Decrease) $’000$’000%Point-of-Care1,8882,16414.6%Clinica

  • GlobeNewswire

    Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results

    Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERNDUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30, 2022. The Company has scheduled a conference call for that same day, Thursday June 30, 2022 at 11:00am ET (4:00pm BST) to discuss the results of

  • GlobeNewswire

    Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test

    DUBLIN, Ireland, May 20, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test throughout the European Union as well as other countries that recognise the CE Mark designation. In addition to its ease-of-use and impressive speed to result, in extensive clinical trails the test has demonstrated excellent 99% sensitiv